AL-S Pharma Companies
AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.
Connections
Estimated Revenue:
$1.6 trillion
Industry:
mHealth (Wearables)
Founded Date:
2016
Headquarters:
Schlieren, Zurich, Switzerland